AUTHORS
Julio Chavez, MD, Michael Dickinson, MBBS (Hons), DMedSci FRACP, FRCPA2, Javier L. Munoz, MD, MBA3, Matthew L. Ulrickson, MD4, Frederick L. Locke, MD5, Catherine Thieblemont, MD, PhD6, Olalekan Oluwole, MD, MPH7, Alex Francisco Herrera, MD8, Chaitra Ujjani, MD9, Yi Lin Jr, MD, PhD10, Peter A. Riedell, MD11, Natasha Kekre, MD12, Sven de Vos, MD, PhD13, Jacob Wulff, PhD14, Xiang Fang, PhD15, Olga Nikolajeva, MD16, Harry Miao, MD, PhD17, Jenny J. Kim, MD, MS18, Sattva S Neelapu Sr, MD19
AFFILIATIONS
1 Mayo Clinic, Jacksonville, Florida, United States
2 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Victoria, Australia
3 Mayo Clinic, Phoenix, Arizona, United States
4 Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Paris City University, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis,, Paris, France
7 Vanderbilt University Medical Center, Nashville, Tennessee, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois, United States
12 The Ottawa Hospital, Ottawa, Ontario, Canada
13 David Geffen School of Medicine at UCLA, Santa Monica, California, United States
14 Kite, a Gilead Company, Santa Monica, California, United States
15 Kite, a Gilead Company, Santa Monica, California, United States
16 Kite, a Gilead Company, Santa Monica, California, United States
17 Kite, a Gilead Company, Santa Monica, California, United States
18 Kite, a Gilead Company, Santa Monica, California, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Introduction: Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for and has shown curative potential in the second line (Westin, et al. NEJM. 2023) or later (Neelapu, et al. Blood. 2023) treatment of LBCL. In the 3-year follow-up analysis of ZUMA-12 (NCT03761056), a Phase 2, multicenter, single-arm study of axi-cel as part of first-line treatment for high-risk LBCL (n=37 response-evaluable pts), axi-cel demonstrated an 86% investigator-assessed complete response (CR) rate and a 92% objective response rate (ORR); 73% of evaluable pts were in ongoing response (all CR), with no new safety signals observed after the primary analysis (Chavez, et al. Blood. 2025). Here, we report a long-term follow-up analysis of axi-cel efficacy and safety from ZUMA-12 after a median follow-up of ≥70 mo.
Methods: Eligible adults had high-risk LBCL, defined by double- or triple-hit histology (MYC and BCL2 and/or BCL6 rearrangements) per investigator or an International Prognostic Index (IPI) score ≥3. Pts must have also had positive interim PET per Lugano classification (Deauville score 4 or 5) after 2 cycles of an anti-CD20 monoclonal antibody and anthracycline-containing regimen. Pts underwent leukapheresis, optional non-chemotherapy bridging per the investigator’s discretion, and lymphodepleting chemotherapy followed by a single axi-cel infusion (2×106 CAR T cells/kg). Efficacy was evaluated in the response-evaluable population (ie, centrally confirmed double- or triple-hit histology and/or IPI score ≥3) and safety among all treated pts. The primary endpoint was investigator-assessed CR rate per Lugano classification (Cheson, et al. J Clin Oncol. 2014). Secondary endpoints included ORR per investigator assessment, duration of response (DOR), event-free survival (EFS), progression-free survival (PFS), overall survival (OS), and incidence of adverse events (AEs). Exploratory analyses included lymphoma-specific survival by cumulative incidence of disease progression and/or death (with non-relapse mortality as a competing risk) and a landmark analysis of efficacy outcomes in pts with CR at 6 mo. For DOR, EFS, PFS, OS, and exploratory analyses, data were combined from the original study and a separate long-term follow-up (LTFU) study.
Results: As of November 16, 2025, 42 pts were enrolled and 40 were treated with axi-cel, with a median follow-up of 71.4 mo (range, 60.0-80.7). A total of 37 pts were evaluable for response. The CR rate was 86% (95% CI, 71-95) and 70% (26/37) remained in CR at data cutoff without subsequent antilymphoma therapy. Median DOR, EFS, PFS, and OS were not reached (95% CI, not evaluable [NE]-NE) with longer follow-up; 60-mo estimates were 77.9% (95% CI, 59.0-88.9), 69.7% (95% CI, 51.8-82.0), 71.6% (95% CI, 53.6-83.7), and 78.1% (95% CI, 60.9-88.4), respectively.
In the response-evaluable population (n=37), the cumulative incidence of disease progression or lymphoma-specific death at 60 mo was 22.2% (95% CI, 10.3-36.9). The 60-mo cumulative incidence of lymphoma-specific death was 16.2% (95% CI, 6.5-29.9). For pts with continuous CR at 6 mo (n=26), median EFS, PFS, and OS were all not reached (95% CI, NE-NE) and 60-mo estimates were 95.2% (95% CI, 70.7-99.3), 95.2% (95% CI, 70.7-99.3), and 95.8% (95% CI, 73.9-99.4), respectively.
Since the 3-year analysis, 29 pts consented (3 did not: 2 in CR, 1 in partial response) to the LTFU study. Safety events since rollover to LTFU included 1 subsequent malignancy (Grade 3 squamous cell carcinoma of skin; considered unrelated to axi-cel) and 2 axi-cel–related AEs in 1 pt (Grade 2 hypogammaglobulinemia and Grade 2 upper respiratory tract infection) that were ongoing at the time of rollover. No new cases of cytokine release syndrome or neurologic events were reported since the primary analysis. One death (due to heart failure and pneumonia while in CR) occurred after the 3-year analysis. There were no pts with disease progression since the 3-year analysis.
Conclusions: Axi-cel demonstrated durable remissions lasting ≥5 years and median OS was not reached, supporting its curative potential for a substantial proportion of high-risk pts treated in the first-line setting. No new safety signals were identified with >5 years of follow-up. Results from the ongoing Phase 3 randomized controlled trial ZUMA-23 (NCT05605899) of first-line axi-cel versus standard of care in high-risk (IPI 4-5) LBCL are awaited.
DISCLOSURES
Julio Chavez, MD: GenMab - Research Funding; Incyte - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); ADC therapeutics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Allogene - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)